News | Genetic Testing | January 13, 2025

‘Express License’ Platform Now Offered by ERS Genomics

An Express License provides fast, simple and affordable access to company's patent portfolio through a non-exclusive internal research license.


Jan. 13, 2025 -- ERS Genomics, the CRISPR licensing company, has announced the launch of its Express License platform to provide small research enterprises and startups with affordable and rapid access to the world’s largest foundational and essential CRISPR/Cas9 patent portfolio.

ERS Genomics is committed to providing responsible and effective access to CRISPR/Cas9 technology. To support small and early-stage organizations, ERS now offers a non-exclusive Express License for internal research use, specifically designed for companies with fewer than 15 employees and under $10 million in funding. This streamlined licensing option enables a broader spectrum of innovators to access CRISPR/Cas9 intellectual property in a cost-effective and efficient way, fostering groundbreaking research and development in areas such as synthetic biology, disease modeling, gene editing, high-throughput screening and functional genomics.

Professor Emmanuelle Charpentier, Nobel Prize Winner & ERS Genomics Co-Founder, said, "Our new express license platform represents an exciting step forward in democratizing access to the foundational CRISPR/Cas9 IP. By simplifying the process and making it more affordable, we’re empowering startups and small companies to innovate and bring groundbreaking solutions to the forefront of science and industry."

Candidate organizations can secure an Express License by demonstrating their eligibility through scientific credentials such as research publications, academic collaborations, or technology-related patents. Interested organizations can verify their eligibility and submit their application through ERS' online platform.

John E Milad, CEO, ERS Genomics, said, "Our new Express License platform streamlines and accelerates access to CRISPR/Cas9, making it more affordable than ever for smaller organizations. This initiative represents a major step toward democratizing this Nobel Prize-winning technology, empowering companies of all sizes to harness its transformative potential. We are proud to provide the industry's most accessible and cost-effective solution for accessing foundational CRISPR/Cas9 intellectual property, honoring Prof. Charpentier’s enduring spirit of innovation."

Additional information is available at ERS Express License.

Current licensees include GSK, Merck, Bayer, ThermoFisher Scientific, Corteva, Lonza, Taconic, Danaher, PerkinElmer, Charles River Laboratories, Synthego and Cargill. For additional information please visit www.ersgenomics.com.


Related Content

News | Genetic Testing
March 22, 2022 – A Scripps Research team developed a smartphone app that can calculate users’ genetic risk for coronary ...
Home March 22, 2022
Home
Feature | Genetic Testing

In a large-scale study of people from diverse ancestries, researchers narrowed down the number of genomic variants that ...

Home December 17, 2021
Home
Videos | Genetic Testing

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at ...

Home November 22, 2021
Home
News | Genetic Testing

June 12, 2019 – Specialized risk scores derived from testing that calculates the cumulative effect of an individual’s ...

Home June 12, 2019
Home
Feature | Genetic Testing | Andrew Waxler, M.D., FACC

The diagnosis and management of cardiovascular disease has long followed a familiar approach. Patients see their ...

Home December 13, 2017
Home
News | Genetic Testing

November 9, 2016 — The recent, sudden death of a 13-year-old boy resulted in more than 20 relatives being incorrectly ...

Home November 09, 2016
Home
News | Genetic Testing

July 26, 2016 — A new study has identified a genetic error that weakens the aorta, placing patients with this and ...

Home July 26, 2016
Home
Feature | Genetic Testing | Kevin P. Greene, M.D.

Statins are lifesaving medications — they have been shown to greatly reduce heart attack and other related events by ...

Home December 22, 2015
Home
Technology | Genetic Testing

October 8, 2015 — Invitae Corp., a genetic information company, announced the expansion of its cardiology offering ...

Home October 08, 2015
Home
Feature | Genetic Testing

September 21, 2015 — The U.S. Food and Drug Administration (FDA) will hold a pair of public workshops in November to ...

Home September 21, 2015
Home
Subscribe Now